Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Dec 24;99(26):16951-6.
doi: 10.1073/pnas.252648899. Epub 2002 Dec 13.

Disruption of T helper 2-immune responses in Epstein-Barr virus-induced gene 3-deficient mice

Affiliations

Disruption of T helper 2-immune responses in Epstein-Barr virus-induced gene 3-deficient mice

Edward E S Nieuwenhuis et al. Proc Natl Acad Sci U S A. .

Abstract

Epstein-Barr virus-induced gene 3 (EBI3) is a widely expressed IL-12p40-related protein that associates as a heterodimer with either IL-12p35 or an IL-12p35 homologue, p28, to create a new cytokine (IL-27). To define the function of EBI3 in vivo, we generated knockout mice in which the ebi3 gene was targeted by homologous recombination. EBI3-/- mice exhibited normal numbers of both naive and mature CD4+ and CD8+ T cells and B cells, but markedly decreased numbers of invariant natural killer T cells (iNKT) as defined by staining with an alpha-galactosylceramide (alphaGalCer)-loaded CD1d-tetramer. iNKT cells from EBI3-/- mice exhibited decreased IL-4 and, to a lesser extent, IFN-gamma production after alphaGalCer stimulation in vitro. A sustained decrease in IL-4 production was also observed in EBI3-/- mice after alphaGalCer stimulation in vivo in contrast to IFN-gamma production, which was only transiently decreased under such stimulation. Notably, EBI3-/- mice were resistant to the induction of immunopathology associated with oxazolone-induced colitis, a colitis model mediated primarily by T helper (Th) 2-type cytokine production by iNKT cells. In contrast, trinitrobenzene sulfonic acid-induced colitis, a predominantly Th1-mediated colitis model, was unaffected. Thus, EBI3 plays a critical regulatory role in the induction of Th2-type immune responses and the development of Th2-mediated tissue inflammation in vivo, which may be mediated through the control of iNKT cell function.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
Generation of the EBI3−/− mouse strain. (A) Exons 2–5, encoding amino acids 24–228 of the EBI3 protein, were replaced by the Neo gene cassette under control of the phosphoglycerate kinase promoter (PGK-Neo) inserted in the same orientation as the ebi3 gene. (B) Southern analysis of PvuII- and HindIII-digested genomic DNA from ganciclovir/G-418-resistant embryonic stem cell clone A12 using 32P-labeled right (R) and left (L) probes. Clones showing the expected recombinant band at 8.4 kb with the R probe (Upper) were further screened by hybridization with the L probe (Lower), which revealed the expected recombinant band of 13.9 kb. (C) Southern analysis of genomic DNA from homozygous WT (+/+), homozygous mutant (−/−), and heterozygous (+/−) mice. BamHI-digested DNA was hybridized with 32P-labeled EBI3 cDNA. BamHI fragments predicted to contain the left side of exon 1 (2.8 kb) are present in all three samples at equal levels, whereas fragments containing the right side of exon 1 and exons 2 and 3 (3.2 kb), and containing exons 4 and 5 (0.95 kb) are undetectable (−/− mice) or are present at half molar levels (heterozygotes). A band at ≈2.4 kb detected in all lanes corresponds to the right end of exon 5 in WT and heterozygous DNA, and to a rearranged BamHI fragment of identical size containing the right side of exon 1 linked to the Neo gene in heterozygous and knockout mouse DNA. (D) Northern blot of RNA from spleens of EBI3 WT (+/+), heterozygous (+/−), and knockout (−/−) mice hybridized to 32P-labeled EBI3 cDNA (EBI3) or beta-actin (Actin) probes. EBI3 transcripts of 1.8 kb are detected in WT (+/+) and heterozygous (+/−) mouse RNA but are undetectable in knockout RNA (−/−).
Fig 2.
Fig 2.
IL-4 defect in EBI3−/− mice. (A) EBI3−/− CD4+ T cells from spleen stimulated with anti-CD3 plus anti-CD28 monoclonal antibodies produce more IFN-γ in comparison with CD4+ T cells from WT control mice. Heterozygous mice exhibited an intermediate pattern of cytokine production. Data are representative of three experiments. (B) Similar levels of IL-12 production by DC from WT and EBI3−/− spleens. Data are representative of two experiments. (C) CD4+ T cells from EBI3−/− mice produce significantly less IL-4 than WT animals when stimulated as in A. (D) IL-4 production in EBI3−/− mice is similar to WT mice in a Th2-inducing environment. Data are representative of three experiments. Bars represent means and standard errors of the means (n = 5). *, P < 0.05, compared with the respective WT control group. **, P < 0.002, compared with the respective WT control group.
Fig 3.
Fig 3.
iNKT cell defect in EBI3−/− mice. (A) Liver and spleen mononuclear cells were stained with anti-CD3 and an αGalCer-loaded CD1d tetramer. iNKT cell numbers are reduced in the liver and spleen of EBI3−/− mice compared with WT animals. A representative flow cytometry analysis is shown. (B) Intrahepatic lymphocytes from WT (filled bars) or EBI3−/− (open bars) were stimulated with αGalCer. IFN-γ (Right) and IL-4 (Left) levels were determined by ELISA at 24 and 48 h. EBI3−/− iNKT cells exhibited decreased αGalCer-stimulated IL-4 production. No cytokines were detected with the control lipid βGalCer (data not shown). (C) WT (filled bars) and EBI3−/− mice (open bars) received 2 μg of αGalCer i.p., and serum IL-4 and IFN-γ levels were assessed at 2, 4, and 24 h by ELISA. EBI3−/− mice exhibit impaired IL-4 production after in vivo stimulation with αGalCer at all time points, whereas IFN-γ production is decreased only at 4 h after stimulation. ND, not detectable; *, P < 0.05; **, P < 0.005; ***, P < 0.0005.
Fig 4.
Fig 4.
Selective protection from Th2-mediated immunopathology in EBI3−/− mice. (A) Weight loss after induction of oxazolone colitis was limited to 5% in both EBI3−/− and EBI3+/− mice in comparison with 15% in WT littermates. Both EBI3−/− and EBI3+/− exhibited complete clinical recovery on day 5 after disease induction. *, P < 0.02. (B) Almost complete absence of macroscopic signs of disease in EBI3−/− and EBI3+/− mice 5 days after induction of oxazolone colitis. (C) WT mice exhibit severe histopathologic evidence of colitis, whereas EBI3−/− mice show only mild inflammatory signs. (D) Significant reduction in inflammatory score in EBI3−/− and EBI3+/− mice compared with WT mice. (E) Significantly reduced IL-4 production and a trend toward increased IFN-γ production of lamina propria mononuclear cells from EBI3−/− mice in comparison with WT control mice. (F) Nuclear extracts from spleen T cells from oxazolone-treated WT (n = 3) and EBI3−/− (n = 4) mice analyzed by Western blotting for GATA-3 (50-kDa band) expression. Control Western blotting for β-actin showed equal loading in all lanes (data not shown). (G) Similar clinical response (weight loss) after TNBS administration in EBI3−/− and EBI3+/− mice in comparison with WT mice. No significant weight loss was observed in an ethanol control group of WT and EBI3−/− mice (data not shown). (H) No significant difference in pathological score among EBI3−/−, EBI3+/−, and WT mice in TNBS-induced colitis. Bars represent means and standard errors of the means. Data are representative of three experiments with five mice per group. *, P < 0.05 (in D and E), compared with the respective WT control groups.

Similar articles

Cited by

References

    1. Thierfelder W. E., van Deursen, J. M., Yamamoto, K., Tripp, R. A., Sarawar, S. R., Carson, R. T., Sangster, M. Y., Vignali, D. A., Doherty, P. C., Grosveld, G. C. & Ihle, J. N. (1996) Nature 382, 171-174. - PubMed
    1. Asnagli H. & Murphy, K. M. (2001) Curr. Opin. Immunol. 13, 242-247. - PubMed
    1. Murphy T. L., Cleveland, M. G., Kulesza, P., Magram, J. & Murphy, K. M. (1995) Mol. Cell. Biol. 15, 5258-5267. - PMC - PubMed
    1. Tew J. G., Wu, J., Fakher, M., Szakal, A. K. & Qin, D. (2001) Trends Immunol. 22, 361-367. - PubMed
    1. Maldonado-Lopez R., De Smedt, T., Michel, P., Godfroid, J., Pajak, B., Heirman, C., Thielemans, K., Leo, O., Urbain, J. & Moser, M. (1999) J. Exp. Med. 189, 587-592. - PMC - PubMed

Publication types